Linagliptin Add-on to Insulin Background Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT02897349

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02897349
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02897349. Randomized; double masking; primary purpose treatment. Start 2016-09-30 (actual); primary completion 2019-01-11 (actual). Results posted on 2020-01-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin Add-on to Insulin Background Therapy
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
placebo
Intervention (Drug)
linagliptin
Intervention (Drug)
background therapy
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02897349
Content hash
b54f4d385dd75ffc09ddb16866ef4742ce33e3923fc8adafa68a807cb37d6701